Citation Impact
Citing Papers
SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Diversity oriented clicking delivers β-substituted alkenyl sulfonyl fluorides as covalent human neutrophil elastase inhibitors
2022 StandoutNobel
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
2006
Striking Oxygen Sensitivity of the Peptidylglycine α-Amidating Monooxygenase (PAM) in Neuroendocrine Cells
2015 StandoutNobel
Mechanisms of Thrombus Formation
2008 Standout
Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat
2006
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel
2007
Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression
2003
Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor Receptor
2009 StandoutNobel
Enantioselective Intramolecular CH Amination Catalyzed by Engineered Cytochrome P450 Enzymes In Vitro and In Vivo
2013 StandoutNobel
Mechanisms and Functional Implications of Adult Neurogenesis
2008 Standout
Drug-Dependent Requirement of Hippocampal Neurogenesis in a Model of Depression and of Antidepressant Reversal
2008
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
Nucleotide signalling during inflammation
2014 StandoutNature
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
2003
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450
2006
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma
2009
High-resolution crystal structure of human protease-activated receptor 1
2012 StandoutNatureNobel
New Antithrombotic Drugs
2012
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007
Transition-state analysis of nucleoside hydrolase from Crithidia fasciculata
1991
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial
2007
Design and Synthesis of a Homogeneous Erythropoietin Analogue with Two Human Complex‐Type Sialyloligosaccharides: Combined Use of Chemical and Bacterial Protein Expression Methods
2009 StandoutNobel
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase
1989
Protease‐activated receptors in hemostasis, thrombosis and vascular biology
2005
Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis
1997
Inhibitory effect of pentalenolactone on vascular smooth muscle cell proliferation
2001
New insights into copper monooxygenases and peptide amidation: structure, mechanism and function
2000
Platelet Activation and Atherothrombosis
2007 Standout
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
2013 Standout
The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance
2008
Drug discovery for a new generation of covalent drugs
2012
P2Y12, a New Platelet ADP Receptor, Target of Clopidogrel
2001
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Factor analysis of Forced Swimming test, Sucrose Preference test and Open Field test on enriched, social and isolated reared rats
2006
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
2008
Organocatalytic Asymmetric Hydrolysis of Epoxides
2014 StandoutNobel
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
2007
Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>
2005
Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
2008
Oxytocin increases trust in humans
2005 StandoutNature
Post-translational modifications in the context of therapeutic proteins
2006
The HPA axis in major depression: classical theories and new developments
2008 Standout
Involvement of vasopressin in affective disorders
2008
Major Depressive Disorder
2008 Standout
Crystal Structure of the Non-heme Iron Dioxygenase PtlH in Pentalenolactone Biosynthesis
2007 StandoutNobel
Inhibition of Carnitine Palmitoyltransferase I Augments Sphingolipid Synthesis and Palmitate-induced Apoptosis
1997 StandoutNobel
The P2Y12 receptor regulates microglial activation by extracellular nucleotides
2006 StandoutNobel
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy
2006
Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-α Secretion and Signaling through a Nucleotide Receptor
2002 StandoutNobel
Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies
2015
Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine
2004
Gi‐dependent and ‐independent mechanisms downstream of the P2Y12 ADP‐receptor
2004
Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click Chemistry
2014 StandoutNobel
The molecular neurobiology of depression
2008 StandoutNature
Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication
2004
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Identification of the platelet ADP receptor targeted by antithrombotic drugs
2001 StandoutNatureNobel
Platelet-Active Drugs
2001
Pharmacological profiles of cloned mammalian P2Y-receptor subtypes
2005
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in Caenorhabditis elegans
2015 StandoutNobel
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Enantioselective α-Hydroxylation of 2-Arylacetic Acid Derivatives and Buspirone Catalyzed by Engineered Cytochrome P450 BM-3
2006 StandoutNobel
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
2006
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
Selective Differentiation of Neural Progenitor Cells by High-Epitope Density Nanofibers
2004 StandoutScience
Covalent Modifiers: An Orthogonal Approach to Drug Design
2009
Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel
2005
The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis.
2007
Aldolase Antibodies of Remarkable Scope
1998 StandoutNobel
Biocompatible SuFEx Click Chemistry: Thionyl Tetrafluoride (SOF4)‐Derived Connective Hubs for Bioconjugation to DNA and Proteins
2019 StandoutNobel
The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
2010
Regulation of differentiated properties and proliferation of arterial smooth muscle cells.
1990
Nucleoside hydrolase from Crithidia fasciculata. Metabolic role, purification, specificity, and kinetic mechanism.
1991
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Rational Tuning of Fluorobenzene Probes for Cysteine‐Selective Protein Modification
2018 StandoutNobel
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
The resurgence of covalent drugs
2011
Electrostatic Basis for Enzyme Catalysis
2006 StandoutNobel
A Heck–Matsuda Process for the Synthesis of β‐Arylethenesulfonyl Fluorides: Selectively Addressable Bis‐electrophiles for SuFEx Click Chemistry
2016 StandoutNobel
Fmoc-Based Synthesis of Peptide-αThioesters: Application to the Total Chemical Synthesis of a Glycoprotein by Native Chemical Ligation
1999 StandoutNobel
Microcontact Printing for Precise Control of Nerve Cell Growth in Culture
1999
Palladium‐Catalyzed Fluorosulfonylvinylation of Organic Iodides
2017 StandoutNobel
Vasopressin and Oxytocin Excite Distinct Neuronal Populations in the Central Amygdala
2005 Science
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants
2003 StandoutScience
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
2004 Standout
Recent Advances in the Chemoenzymatic Synthesis of Carbohydrates and Carbohydrate Mimetics
1996
A Catalytic Enantioselective Route to Hydroxy-Substituted Quaternary Carbon Centers: Resolution of Tertiary Aldols with a Catalytic Antibody
1999 StandoutNobel
A New Portal to SuFEx Click Chemistry: A Stable Fluorosulfuryl Imidazolium Salt Emerging as an “F−SO2+” Donor of Unprecedented Reactivity, Selectivity, and Scope
2017 StandoutNobel
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Works of Marc Pascal being referenced
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
2002
Protein Kinase C α Expression Is Required for Heparin Inhibition of Rat Smooth Muscle Cell Proliferation in Vitro and in Vivo
1996
Defined Glycosaminoglycan Motifs Have Opposite Effects on Neuronal Polarity in Vitro
1994
Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist
2002
Structure and Stereochemistry of the Active Metabolite of Clopidogrel
2002
Detection of atherosclerotic plaque with two monoclonal antibodies 2P1A2 monoclonal antibody is specific for smooth muscle cells in atherosclerotic plaque
1988
Identification and Biological Activity of the Active Metabolite of Clopidogrel
2000
Chapter 15 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands
2002
High sensitivity of carnitine acyltransferase I to malonyl‐CoA inhibition in liver of obese Zucker rats
1985
A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations
1987
Calf‐Spleen Nicotinamide‐Adenine Dinucleotide Glycohydrolase Kinetic Mechanism
1976
On the mechanism of action of calf spleen NAD+ glycohydrolase
1979
SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. II: In Vivo Pharmacological Characterization
1999